Author

S. Levesque

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Assay:whole-genome sequencing· 2 Organism:bacteria (other)· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

F. Grenier· 3 shared L.-P. Haraoui· 3 shared S. Rodrigue· 3 shared P. G. Higgins· 2 shared A. A. Fayad· 1 shared A. Cantin· 1 shared A. J. I. Quenum· 1 shared A. M. Hammerum· 1 shared

Activity by Year

2022-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

F. Grenier

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Emergence of Acinetobacter baumannii International Clone 10 predominantly found in the Middle East

N. Karah, N. Faille, F. Grenier, A. A. Fayad, P. G. Higgins, L. Al-Hassan, B. A. Evans, L. Poirel, R. Bonnin, A. M. Hammerum, F. Hansen, R. Rafei, M. Hamze, X. Didelot, S. Castillo-Ramirez, , L.-P. Haraoui

The paper reports genomic and epidemiological data on a novel Acinetobacter baumannii international clone, IC10, predominantly found in the Middle East.

bioRxiv · Oct 9, 2023 · PreprintMicrobiology

Pharmacological control of CAR T cells through CRISPR-driven rapamycin resistance

S. Levesque, G. Carleton, V. Duque, C. Goupil, J.-P. Fiset, S. Villeneuve, E. Normandeau, G. Morin, N. Dumont, B. H. Nelson, J. Laganiere, B. Boyle, J. J. Lum, Y. Doyon

This study develops a CRISPR-based method to create rapamycin-resistant CAR-T cells, enabling pharmacological control of their activity in cancer therapy.

bioRxiv · Sep 14, 2023 · PreprintCancer Biology

Earliest observation of the tetracycline destructase tet(X3)

F. Grenier, S. Levesque, S. Rodrigue, L.-P. Haraoui

The paper reports the earliest observation of tet(X3) in a clinical strain before tigecycline commercialization, indicating non-tigecycline selective pressures contributed to its emergence.

bioRxiv · Aug 29, 2023 · PreprintMicrobiology

SARS-CoV-2 spike antigen-specific B cell and antibody responses in pre-vaccination period COVID-19 convalescent males and females with or without post-covid condition

M.-A. Limoges, A. J. I. Quenum, M. M. H. Chowdhury, F. Rexhepi, M. Namvarpour, S. A. Akbari, C. Rioux-Perreault, M. Nandi, J.-F. Lucier, S. Lemaire-Paquette, L. Premkumar, Y. Durocher, A. Cantin, S. Levesque, A. Menendez, , S. Ramanathan

This study examines B cell and antibody responses to SARS-CoV-2 antigens in individuals with and without post-COVID condition (PCC), finding sex-related differences in antibody responses to the spike protein.

bioRxiv · Apr 13, 2023 · PreprintImmunology

Molecular epidemiology of carbapenemase-producing Acinetobacter spp. from Israel, 2001-2006: earliest report of blaNDM predating the oldest known blaNDM-positive strains

F. Grenier, V. Baby, S. Allard, F. Heynemand, S. Levesque, R. Sullivan, H. L. Landecker, P. G. Higgins, S. Rodrigue, L.-P. Haraoui

This study identifies carbapenemase genes in Acinetobacter spp. from Israel between 2001-2006, finding the earliest reported blaNDM-1 in an A. junii isolate from 2004.

bioRxiv · Jun 3, 2022 · PreprintMicrobiology